Gradientech announces outcome of rights issue

The diagnostics company Gradientech AB (publ) ("Gradientech" or the "Company") today announces the outcome of the new issue of shares with preferential rights for existing shareholders (the "Rights Issue") resolved by the Board of Directors on December 17, 2024. The Rights issue was fully subscribed, which means that Gradientech will receive approximately SEK 60.6 million before deduction of issue costs.

The subscription period for the Rights Issue expired on January 31, 2025. The final outcome shows that 1,728,954 shares, corresponding to approximately 50 percent of the Rights Issue, were subscribed for with subscription rights and 1,735,105 shares, corresponding to approximately 50 percent of the Rights Issue, without subscription rights. Through the Rights Issue, the Company’s share capital will increase by
SEK 346,405.90 to SEK 3,233,123.20 and the number of shares will increase by 3,464,059 shares to 32,331,232 shares.

Approximately one week after the Rights Issue has been registered with the Swedish Companies Registration Office, which is expected to take place in February 2025, BTA will be converted into shares. Allotment of shares subscribed for without subscription rights has been made in accordance with the principles set out in the prospectus prepared in connection with the Rights Issue and published by the Company on
December 20, 2024. Notification of allotment will be made by means of a settlement note to each subscriber. Allocated shares shall be paid in accordance with the instructions on the settlement note.

No compensation is paid for submitted subscription commitments. Aqurat Fondkommission AB is acting as issuing agent and Advokatfirman Lindahl KB is acting as legal advisor to Gradientech in connection with the issue.

For further information, please contact:

Sara Thorslund, PhD, CEO  
Phone: +46 (0)736 29 35 80  

 

Urban Adolfsson, CFO

Phone: + 46 708 20 72 09

 

About Gradientech

Gradientech is a Swedish company that develops and sells next generation diagnostic solutions in infectious medicine. Our market approved QuickMIC® system, classified as a Breakthrough device by the FDA, makes us a world leader in ultra-rapid antibiotic susceptibility testing, helping patients with bacteraemia and sepsis to quickly receive personalised treatment with the right antibiotic at the right dose. This can save lives, reduce healthcare costs and limit the spread of antibiotic resistance in society – probably one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. For more information, please visit www.gradientech.se